Eli Lilly Open Innovation
The Lilly Open Innovation Drug Discovery (OIDD) Program is founded on the belief that pharmaceutical companies, research institutions and academia share a mutual desire to advance innovative biomedical science. OIDD is a premier collaborative platform that unites global investigators with Lilly scientists to both uncover and create innovation that may positively impact the people we serve.
GlaxoSmithKline Academic Partnerships
Partnering with academic researchers is an important part of our research and development activities. Find out how we work with academic institutions, and what we can offer in terms of mutual benefits to potential research partners.
Pfizer Investigator-Initiated Research
Pfizer R&D’s Investigator-Initiated Research program is an incubator for research projects that advance medical and scientific knowledge about our therapies and generates promising medical interventions. This global program is open to all researchers who are interested in conducting their own research.